MDMA for PTSD Showing Promising Outcomes for Patients in MAPS Phase 3 Trials
“In the pharmaceutical drug development community, this is what you dream about.”
Clinical Trials - Page 3
Positive Effects of Single-Dose Psilocybin Last Nearly 5 Years
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.
Placebo-Controlled Study Finds Psilocybin Formulation is Safe and Well-Tolerated in Healthy Volunteers
The study used an investigational psilocybin formulation called COMP360 developed and produced by COMPASS Pathways.
New Zealand’s Ministry of Health Approves LSD Microdosing Study
The study will examine the effects of microdosing LSD on the everyday lives of the participants.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.
Usona Institute Beginning Phase 2 Clinical Trials Using Psilocybin to Treat Major Depressive Disorder
Enrollment of study volunteers is expected to start within the next two months.
Johns Hopkins Starts Psilocybin Clinical Trial to Treat Anorexia Nervosa
Anorexia has phenomenological parallels to anxiety and addiction, both of which have been shown to improve with psilocybin-assisted interventions.
Australian Hospital to Dose Dying Patients with Synthetic Psilocybin
St Vincent's Hospital of Melbourne, Australia will begin treating patients in April
Psilocybin Receives FDA Breakthrough Treatment Designation
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.